Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30612357 | 1.00 | TSHR (0.61) | TSHRALDH1A1HTTSMN1; SMN2LMNA | |
| SCHEMBL30116188 | 0.82 | TSHR (0.47) | TSHRALDH1A1HTTSMN1; SMN2LMNA | |
| SCHEMBL5470400 | 0.82 | TSHR (0.47) | TSHRALDH1A1HTTSMN1; SMN2LMNA | |
| SCHEMBL18030734 | 0.82 | TSHR (0.47) | TSHRALDH1A1HTTSMN1; SMN2LMNA | |
| SCHEMBL2094684 | 0.81 | TSHR (0.46) | TSHRALDH1A1HTTSMN1; SMN2LMNA | |
| SCHEMBL27815013 | 0.81 | ALDH1A1 (0.49) | TSHRALDH1A1HTTSMN1; SMN2LMNA | |
| SCHEMBL4388213 | 0.80 | GAA (0.46) | TSHRALDH1A1HTTSMN1; SMN2LMNA | |
| SCHEMBL2650024 | 0.79 | TSHR (0.53) | TSHRALDH1A1HTTSMN1; SMN2LMNA | |
| SCHEMBL3847160 | 0.79 | ALDH1A1 (0.50) | TSHRALDH1A1HTTSMN1; SMN2LMNA | |
| SCHEMBL19250213 | 0.79 | TSHR (0.67) | TSHRALDH1A1HTTSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2513054-B1 | BICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF DPP-1 | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-09 | — | — | EP | claimed |
| EP-2042491-A1 | Pyridazines as fungicides | Bayer CropScience AG (DE) | 2009-04-01 | — | — | EP | claimed |
| WO-2008017840-A1 | CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIOUS DISEASES | MERLION PHARMACEUTICALS SA (CH) | 2008-02-14 | — | — | WO | claimed |
| US-7175975-B2 | Photographic material with improved development inhibitor releases | EASTMAN KODAK COMPANY (US) | 2007-02-13 | — | — | US | claimed |
| US-20060008751-A1 | Photographic material with improved development inhibitor releasers | EASTMAN KODAK COMPANY | 2006-01-12 | — | — | US | claimed |
| US-6967197-B2 | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-11-22 | — | — | US | claimed |
| US-20030134849-A1 | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-17 | — | — | US | claimed |
| WO-2003018019-A2 | NEW USE OF CYCLIC COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-06 | — | — | WO | claimed |
| EP-1189891-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-03-27 | — | — | EP | claimed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | claimed |
| WO-2001000594-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-01-04 | — | — | WO | claimed |
| US-4143034-A | LIGHTFAST | STERLING DRUG INC. (US) | 1979-03-06 | — | — | US | claimed |
| CN-120987794-B | N-p-hydroxyphenyl-N-methyl-2-acetyl acrylamide compound, and preparation method and application thereof | 中国农业大学 | 2026-05-15 | — | — | CN | disclosed |
| CN-118598766-A | Method for preparing C-7-formamido substituted p-methylene quinone compound | 湖南理工学院 | 2024-09-06 | — | — | CN | disclosed |
| US-12048316-B2 | Sweetener and flavor compositions, methods of making and methods of use thereof | EPC NATURAL PRODUCTS CO., LTD. (CN) | 2024-07-30 | — | — | US | disclosed |
| US-12029228-B2 | Sweetener and flavor compositions, methods of making and methods of use thereof | EPC Natural Products Co., Ltd (CN) | 2024-07-09 | — | — | US | disclosed |
| EP-0509302-A1 | Process for transfer of methine dyes | BASF Aktiengesellschaft (DE) | 1992-10-21 | — | — | EP | disclosed |
| EP-0409117-A1 | Silver halide photographic material | KONICA CORPORATION (JP) | 1991-01-23 | — | — | EP | disclosed |
| US-4971957-A | ANTILIPEMIC AGENTS, ANTICHOLESTEROL AGENTS, BENZENECARBOXAMIDOPHOSPHONATES OR BENZENETHIOCARBOXAMIDOPHOSPHONATES | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1990-11-20 | — | — | US | disclosed |
| US-4880933-A | INSECTICIDES | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1989-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134849-A1 | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | MMP9, MMP1, MMP3 | TSHR 262/4885ALDH1A1 543/4885HTT 2364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.